Diabetes Education News

ORLANDO — An international consensus group has offered the first guidance for clinicians about how to monitor people who test positive for islet autoantibodies, indicating high risk for developing type 1 diabetes.

ORLANDO — Adults with type 1 diabetes had larger reductions in HbA1c using a mobile app that made recommended adjustments to insulin therapy than users who did not receive weekly adjustments, according to a speaker.

ORLANDO — Among adults with obesity-related heart failure with preserved ejection fraction, women taking semaglutide lost significantly more weight than men, but greater weight loss did not result in extra health benefits for women vs. men.

ORLANDO — The generic lipid-lowering drug fenofibrate was associated with a significant reduction in progression of diabetic retinopathy and maculopathy, researchers reported.

ORLANDO — Continuous glucose monitoring metrics can predict imminent stage 3 type 1 diabetes for people who are islet autoantibody positive, according to a speaker at the American Diabetes Association Scientific Sessions.

ORLANDO — In this video exclusive, Osagie Ebekozien, MD, MPH, CPHQ, chief medical officer at T1D Exchange, talks about a victory in increasing access to continuous glucose monitors.

ORLANDO — Health care inequities led to some children and adolescents starting continuous glucose monitoring more than 6 months after a type 1 diabetes diagnosis, according to data presented here.

ORLANDO — In this video exclusive, Osagie Ebekozien, MD, MPH, CPHQ, chief medical officer at T1D Exchange, describes how the organization is moving research into practice.

ORLANDO — Adults with obesity who reduce their body weight lower their odds for developing an obesity-related cancer, according to data presented at the American Diabetes Association Scientific Sessions.

ORLANDO — An inhaled insulin was noninferior to usual care for change in HbA1c and continuous glucose monitoring metrics among adults with type 1 diabetes, according to data from the INHALE-3 trial.